Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: J Neurooncol. 2010 Jan 9;99(1):73–80. doi: 10.1007/s11060-009-0103-2

Table 2.

Frequency of Grade ≥ 3 drug-related adverse events as a function of UGT1A1*28 genotype and EIAC status

Patient group UGT 1A1*28 genotype P value
6/6 6/7 or 7/7
Non-EIAC, no Grade 3+ AE 5 0 0.011
Non-EIAC, ≥1 Grade 3+ AE 8 16
EIAC, no Grade 3+ AE 0 3 1.0
EIAC, at least one Grade 3+ AE 3 10

EIAC enzyme-inducing anticonvulsants; AE adverse events (CTC version 2.0)